First Time Loading...

Novavax Inc
NASDAQ:NVAX

Watchlist Manager
Novavax Inc Logo
Novavax Inc
NASDAQ:NVAX
Watchlist
Price: 4.93 USD 4.67% Market Closed
Updated: May 4, 2024
Section:
 

Wall Street
Price Targets

NVAX Price Targets Summary
Novavax Inc

Wall Street analysts forecast NVAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NVAX is 15.71 USD with a low forecast of 4.04 USD and a high forecast of 39.9 USD.

NVAX Lowest Forecast
Wall Street Target
4.04 USD
18% Downside
NVAX Average Forecast
Wall Street Target
15.71 USD
219% Upside
NVAX Highest Forecast
Wall Street Target
39.9 USD
709% Upside
Lowest
Price Target
4.04 USD
18% Downside
Average
Price Target
15.71 USD
219% Upside
Highest
Price Target
39.9 USD
709% Upside
Novavax Inc Competitors:
Price Targets
C
049960
Cell Biotech Co Ltd
364% Upside
MNKD
MannKind Corp
65% Upside
SERA
Sera Prognostics Inc
75% Downside
KRTX
Karuna Therapeutics Inc
2% Downside
C
049960
Cell Biotech Co Ltd
364% Upside
MNKD
MannKind Corp
65% Upside
SERA
Sera Prognostics Inc
75% Downside
KRTX
Karuna Therapeutics Inc
2% Downside
CYTH
Cyclo Therapeutics Inc
123% Upside
688266
Suzhou Zelgen Biopharmaceuticals Co Ltd
7% Upside
DCPH
Deciphera Pharmaceuticals Inc
6% Upside
ONCO
Oncopeptides AB
107% Upside

Revenue
Forecast

Revenue Estimate
Novavax Inc

For the last 8 years the compound annual growth rate for Novavax Inc's revenue is 51%. The projected CAGR for the next 3 years is -1%.

51%
Past Growth
-1%
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Novavax Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
27%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Novavax Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-83%
Average Miss
What are analyst estimates?

See Also

Summary
NVAX intrinsic value, competitors valuation, and company profile.
DCF Valuation
NVAX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NVAX stock valuation using valuation multiples.
Wall Street Estimates
NVAX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NVAX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NVAX's stock price target?
Price Target
15.71 USD

According to Wall Street analysts, the average 1-year price target for NVAX is 15.71 USD with a low forecast of 4.04 USD and a high forecast of 39.9 USD.

What is Novavax Inc's Revenue forecast?
Projected CAGR
-1%

For the last 8 years the compound annual growth rate for Novavax Inc's revenue is 51%. The projected CAGR for the next 3 years is -1%.

ALPHA SPREAD
Join more than 134,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.